Brent Pfeiffenberger compensation by year
Century Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $49,716 | $625,000 | $640,625 |
| Bonus | $200,000 | $450,000 | — |
| Stock awards | $2,339,779 | $92,614 | $1,869,609 |
| Option awards | $621,167 | $392,000 | $222,681 |
| Non-equity incentive | $24,349 | $360,938 | $317,109 |
| Pension and deferred compensation | $0 | $0 | — |
| All other | $0 | $272,729 | $13,998 |
| Total | $3,235,011 | $2,193,281 | $2,381,022 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Century Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001104659-26-049489, and prior-year filings.
How this page was built: the Century Therapeutics, Inc. filed document, accession 0001104659-26-049489. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 1,587,614 | $1,579,676 | — |
| RSU | 586,887 | $586,953 | — |
| RSU | 521,500 | $518,892 | — |
| RSU | 9,802 | $9,753 | — |
| Option | 31,056 | — | $1.61 |
| Option | 255,792 | — | $1.61 |
| Option | 58,811 | — | $5.32 |
| Option | 521,500 | — | $0.60 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Century Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2025 proxy (filed April 27, 2026)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-13 | Tax withholding | — | 31,172 | $1.65 | 3,602,667 |
| 2026-09-11 | Tax withholding | — | 13,850 | $1.94 | 3,633,839 |
| 2026-09-04 | Tax withholding | — | 463 | $2.11 | 3,633,839 |
| 2026-08-14 | Tax withholding | — | 31,172 | $1.92 | 3,634,302 |
| 2026-06-11 | Tax withholding | — | 13,849 | $2.24 | 3,665,474 |
| 2026-06-05 | Tax withholding | — | 463 | $2.13 | 3,679,323 |
| 2026-05-15 | Tax withholding | — | 31,172 | $2.34 | 3,679,786 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Century Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Brent Pfeiffenberger · this page | President, Chief Executive Officer and Chairman of the Board | $2,381,022 |
| Chad Cowan | Chief Scientific Officer | $1,167,015 |
| Adrienne Farid | Former Chief Development Officer | $989,403 |
| Gregory Russotti | Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | $912,320 |
Board service
Century Therapeutics board · FY2023–FY2024How this board is paid
Company policy: Century Therapeutics pays directors a $40,000 cash retainer. As stated in Century Therapeutics's FY2024 proxy.
The full Century Therapeutics compensation record
free company briefThis page is one person within Century Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Century Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.